Mylan's Combination Drug Gets Tentative FDA Approval Under PEPFAR

Mylan Launches Generic Zomig Tablets

Mylan Q1 Profit Declines - Update

Mylan Q1 Profit Down 17.2%, Reaffirms FY13 Outlook - Quick Facts

Mylan Q1 13 Earnings Conference Call At 4:30 PM ET

Trade MYL now with

2/23/2012 7:34 AM ET

Mylan Inc. (MYL: Quote) said its subsidiary Mylan Laboratories Limited received tentative approval from FDA for its New Drug Application for Abacavir Sulfate and Lamivudine Tablets, 60 mg/30 mg. This fixed-dose combination is intended to treating children with HIV/AIDS. The approval is under the President's Emergency Plan for AIDS Relief or PEPFAR.

The combination is based on the adult-strength, brand version of the product Epzicom, by Viiv Healthcare.

Mylan also has received approval for this pediatric FDC therapy from the World Health Organization under their Prequalification of Medicines Programme.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 188 Articles

Editors Pick

Autodesk Results Miss Estimates; Cuts Outlook

Design software maker Autodesk, Inc. (ADSK) Thursday reported a 30 percent decline in earnings from last year, hurt by lower revenue and weaker margins. The company's quarterly earnings per share, excluding items, came in below analysts' expectations as did its quarterly revenue. At the same time,...

Dell Profit Drops 79% On Sluggish PC Demand

Struggling PC maker Dell Inc. said Thursday after the markets closed that its first quarter profit dropped 79% from last year, as revenue declined and margins deteriorated amid sluggish demand for personal computers. The company's quarterly earnings per share, excluding items, also came in way below analysts' expectations, but its quarterly revenue beat analysts' forecast.

Cisco Results Top Estimates

Cisco Systems, Inc., the world's largest computer networking gear maker, said Wednesday after the markets closed that its third quarter profit rose 14.5% from last year, helped by higher sales and a tax benefit. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly sales.